S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
NASDAQ:BCAB

BioAtla (BCAB) Stock Forecast, Price & News

$2.00
-0.01 (-0.50%)
(As of 09/20/2023 ET)
Compare
Today's Range
$1.98
▼
$2.05
50-Day Range
$1.95
▼
$3.07
52-Week Range
$1.93
▼
$11.73
Volume
187,107 shs
Average Volume
221,641 shs
Market Capitalization
$95.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BioAtla MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
666.7% Upside
$15.33 Price Target
Short Interest
Bearish
10.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$5,080 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.82) to ($2.40) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

552nd out of 961 stocks

Biological Products, Except Diagnostic Industry

84th out of 157 stocks

See Top Rated MarketRank™ Stocks Here

BCAB stock logo

About BioAtla (NASDAQ:BCAB) Stock

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BCAB Price History

BCAB Stock News Headlines

September 17, 2023 | americanbankingnews.com
BioAtla (NASDAQ:BCAB) versus Cardiol Therapeutics (NASDAQ:CRDL) Head to Head Survey
September 6, 2023 | finance.yahoo.com
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 21, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 3, 2023 | finance.yahoo.com
BioAtla to Participate in Upcoming Investor Conferences in August
August 3, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Exelixis (EXEL) and Steris (STE)
August 3, 2023 | msn.com
JP Morgan Maintains BioAtla (BCAB) Overweight Recommendation
August 3, 2023 | msn.com
JMP Securities Reiterates BioAtla (BCAB) Market Outperform Recommendation
August 3, 2023 | finance.yahoo.com
BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call Transcript
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
August 2, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on BioAtla (BCAB)
August 1, 2023 | finance.yahoo.com
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
July 25, 2023 | finance.yahoo.com
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
July 7, 2023 | finance.yahoo.com
With 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional owners
July 6, 2023 | msn.com
BioAtla (BCAB) Price Target Increased by 9.33% to 16.73
June 26, 2023 | finance.yahoo.com
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
May 31, 2023 | finance.yahoo.com
BioAtla to Participate in the Jefferies Healthcare Conference
May 16, 2023 | msn.com
JMP Securities Reiterates BioAtla (BCAB) Outperform Recommendation
May 15, 2023 | markets.businessinsider.com
Where BioAtla Stands With Analysts
May 15, 2023 | msn.com
HC Wainwright & Co. Reiterates BioAtla (BCAB) Buy Recommendation
May 15, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on BioAtla (BCAB)
May 15, 2023 | markets.businessinsider.com
BioAtla (BCAB) Receives a Buy from JMP Securities
May 13, 2023 | msn.com
EF Hutton Reiterates BioAtla (BCAB) Buy Recommendation
May 12, 2023 | markets.businessinsider.com
BioAtla (BCAB) Receives a Buy from BTIG
May 11, 2023 | finance.yahoo.com
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 11, 2023 | investing.com
Bioatla (BCAB) Earnings Dates & Reports
May 8, 2023 | finance.yahoo.com
BioAtla to Participate in the JMP Securities Life Sciences Conference
May 4, 2023 | finance.yahoo.com
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
See More Headlines
Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

BCAB Company Calendar

Last Earnings
8/01/2023
Today
9/21/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCAB
CUSIP
N/A
CIK
1826892
Web
www.bioatla.com
Phone
858-558-0708
Fax
N/A
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+666.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,480,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-77.19%
Return on Assets
-58.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.21
Quick Ratio
5.21

Sales & Book Value

Annual Sales
$250,000.00
Price / Sales
382.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.79 per share
Price / Book
0.53

Miscellaneous

Outstanding Shares
47,803,000
Free Float
43,797,000
Market Cap
$95.61 million
Optionable
Not Optionable
Beta
0.28
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jay M. Short Ph.D. (Age 65)
    Co-Founder, CEO & Chairman
    Comp: $1.06M
  • Mr. Richard A. WaldronMr. Richard A. Waldron (Age 69)
    Sr. VP & CFO
    Comp: $617.62k
  • Dr. Eric L. Sievers M.D. (Age 59)
    Chief Medical Officer
    Comp: $608.18k
  • Mr. Christian J. VasquezMr. Christian J. Vasquez (Age 47)
    Sr. VP of Fin., Corp. Controller & Sec.
    Comp: $408.75k
  • Lisa M. Pelton
    Accounting Mang.
  • Ms. Susie Melody
    Sr. VP of HR
  • Dr. Cathy Chang Ph.D.
    Sr. VP of R&D
  • Dr. Gerhard Frey Ph.D.
    Sr. VP of Technology Devel.
  • Ms. Monica Sullivan
    Sr. VP of Intellectual Property & Contracts
  • Ms. Sheri Lydick
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BCAB Stock - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BCAB shares.
View BCAB analyst ratings or view top-rated stocks.

What is BioAtla's stock price forecast for 2023?

6 Wall Street analysts have issued 12 month price targets for BioAtla's shares. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they expect the company's stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 666.7% from the stock's current price.
View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts.

How have BCAB shares performed in 2023?

BioAtla's stock was trading at $8.25 on January 1st, 2023. Since then, BCAB stock has decreased by 75.8% and is now trading at $2.00.
View the best growth stocks for 2023 here.

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our BCAB earnings forecast.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.13.

What ETF holds BioAtla's stock ?

Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio.

When did BioAtla IPO?

(BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

What is BioAtla's stock symbol?

BioAtla trades on the NASDAQ under the ticker symbol "BCAB."

Who are BioAtla's major shareholders?

BioAtla's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.71%), Wasatch Advisors LP (3.15%), Geode Capital Management LLC (1.74%), State Street Corp (1.49%), Renaissance Technologies LLC (1.44%) and Vontobel Holding Ltd. (1.19%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn.
View institutional ownership trends.

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioAtla's stock price today?

One share of BCAB stock can currently be purchased for approximately $2.00.

How much money does BioAtla make?

BioAtla (NASDAQ:BCAB) has a market capitalization of $95.61 million and generates $250,000.00 in revenue each year. The company earns $-106,480,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How can I contact BioAtla?

The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com.

This page (NASDAQ:BCAB) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -